4-(对氯苯基)-6-甲基-3-氰基-2-吡啶酮 | 134600-03-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-(对氯苯基)-6-甲基-3-氰基-2-吡啶酮
• 英文名称: 4-(p-chlorophenyl)-6-methyl-3-cyano-2-pyridone
• 英文别名: 4-(4-chlorophenyl)-6-methyl-2-oxo-1H-pyridine-3-carbonitrile
• CAS: 134600-03-6
• 化学式: C₁₃H₉ClN₂O
• 分子量: 244.68
• InChiKey: IWFMTBWSTVKGFA-UHFFFAOYSA-N

物化性质

• 沸点：
  434.6±45.0 °C(Predicted)
• 密度：
  1.34±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.08
• 拓扑面积：
  52.9
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  甲基溴化镁 、 4-(对氯苯基)-6-甲基-3-氰基-2-吡啶酮 以 乙醚 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  [EN] GLUN2 SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS
  [FR] ANTAGONISTES SÉLECTIFS DE LA SOUS-UNITÉ GLUN2 DES RÉCEPTEURS DU N-MÉTHYL-D-ASPARTATE

  摘要：

  Compounds that selectively inhibit the GluN2 subunits of NMDA receptors are disclosed. In general, the compounds have superior activity against GluN2C/D subunit(s) over GluN2A/B subunit(s). Optionally, the compounds have a structure of Formulas (I), (II), (III), or other formulas disclosed herein, enantiomers or diastereomers thereof, or pharmaceutically acceptable salts thereof. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a neurological condition or disorder using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary neurological conditions or disorders include Parkinson's disease, dystonia and related motor disorders, depression, neuropsychiatric indications, stoke, hypoxia, traumatic brain injury, acute injuries involving the white matter, Alzheimer's disease, compulsivity and related disorders, and epilepsy.

  公开号：

  WO2022226161A1
• 作为产物：
  描述：

  4-氯苯甲醛 在 sodium ethanolate 作用下， 以 乙醇 为溶剂， 反应 0.01h， 生成 4-(对氯苯基)-6-甲基-3-氰基-2-吡啶酮
  参考文献：
  名称：

  Cascade synthesis of 2-pyridones using acrylamides and ketones

  摘要：

  在微波辅助下，2-氰乙酰胺与芳香醛发生非催化缩合反应，并与丙烯酰胺发生由烯酸酯介导的迈克尔式加成反应，随后发生氧化环化反应，从而以良好至极佳的收率生成 2-吡啶酮。不对称酮会产生两种烯醇异构体，因此丁-2-酮和戊-2-酮的热力学和动力学产物已被分离出来并完全定性。

  DOI：

  10.1039/c4ra06619g

文献信息

• Krstic, Vera; Misic-Vukovic, Milica; Radojkovic-Velickovic, Mirjana, Journal of Chemical Research, Miniprint, 1991, # 4, p. 783 - 792
  作者：Krstic, Vera、Misic-Vukovic, Milica、Radojkovic-Velickovic, Mirjana

  DOI：——

  日期：——
• KRSTIC, VERA;MISIC-VUKOVIC, MILICA;RADOJKOVIC-VELICKOVIC, MIRJANA, J. CHEM. RES. (S),(1991) N, C. 82
  作者：KRSTIC, VERA、MISIC-VUKOVIC, MILICA、RADOJKOVIC-VELICKOVIC, MIRJANA

  DOI：——

  日期：——
• Cascade synthesis of 2-pyridones using acrylamides and ketones
  作者：Sunil K. Rai、Shaziya Khanam、Ranjana S. Khanna、Ashish K. Tewari

  DOI：10.1039/c4ra06619g

  日期：——

  Microwave assisted non-catalytic condensation of 2-cyanoacetamide with aromatic aldehydes, and enolate mediated Michael-type addition to acrylamide followed by oxidative cyclization, produce 2-pyridones in good to excellent yield. Unsymmetrical ketones produce two regioisomeric enolates, therefore thermodynamic and kinetic products of butan-2-one and pentan-2-one have been isolated and fully characterized.

  在微波辅助下，2-氰乙酰胺与芳香醛发生非催化缩合反应，并与丙烯酰胺发生由烯酸酯介导的迈克尔式加成反应，随后发生氧化环化反应，从而以良好至极佳的收率生成 2-吡啶酮。不对称酮会产生两种烯醇异构体，因此丁-2-酮和戊-2-酮的热力学和动力学产物已被分离出来并完全定性。
• [EN] GLUN2 SUBUNIT SELECTIVE ANTAGONISTS OF THE N-METHYL-D-ASPARTATE RECEPTORS<br/>[FR] ANTAGONISTES SÉLECTIFS DE LA SOUS-UNITÉ GLUN2 DES RÉCEPTEURS DU N-MÉTHYL-D-ASPARTATE
  申请人：[en]EMORY UNIVERSITY

  公开号：WO2022226161A1

  公开（公告）日：2022-10-27

  Compounds that selectively inhibit the GluN2 subunits of NMDA receptors are disclosed. In general, the compounds have superior activity against GluN2C/D subunit(s) over GluN2A/B subunit(s). Optionally, the compounds have a structure of Formulas (I), (II), (III), or other formulas disclosed herein, enantiomers or diastereomers thereof, or pharmaceutically acceptable salts thereof. Pharmaceutical formulations containing one or more of the compounds are also disclosed. Additionally, methods of treating a neurological condition or disorder using the compounds or their pharmaceutical formulations thereof are disclosed. Exemplary neurological conditions or disorders include Parkinson's disease, dystonia and related motor disorders, depression, neuropsychiatric indications, stoke, hypoxia, traumatic brain injury, acute injuries involving the white matter, Alzheimer's disease, compulsivity and related disorders, and epilepsy.